Immunex Will Collect Enbrel Juvenile RA Safety/Efficacy Data For Three Years
Immunex has committed to collecting safety and efficacy data of Enbrel in at least 500 juvenile rheumatoid arthritis patients for a minimum of three years, according to FDA's May 27 approval letter for the new arthritis indication.
You may also be interested in...
The next step in Wyeth-Ayerst's plans to expand the market for Enbrel will be the presentation of the pivotal trial data in early rheumatoid arthritis during the upcoming American College of Rheumatology conference in Boston, Nov. 13-17.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011